BMBIF - Bright Minds Biosciences: A Search For The GW Pharmaceuticals Of The Psilocybin Space

• While the hype around psychedelic stocks and alternative mental health treatments has seemingly cooled over the past few months, the industry is still ripe with opportunity.
• Long-term investors looking to ride the wave of novel mental health treatments should pay close attention to the pipelines of newcomers in the space.
• Companies like Bright Minds Biosciences are focused on targeting alternative 5-HT receptors that presumably offer greater health benefits with less risk.
• Products that avoid hitting the 5-HT2B receptor seem to have the most long-term market potential.

For further details see: